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remissions with a low
risk of CNS progression.
Survival of patientswith high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and
the risk of central nervous system (CNS) progression is relatively high. We conducted
a phase 2 trial in 139 patients aged 18 to 64 years who had primary DLBCL with an
age-adjusted International Prognostic Index (aaIPI) score of 2 to 3 or site-specific risk factors
for CNS recurrence. The goal was to assess whether a dose-dense immunochemotherapy
with early systemic CNS prophylaxis improves the outcome and reduces the incidence of
CNS events. Treatment consisted of 2 courses of high-dosemethotrexate in combinationwith
biweekly rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP-14), followed by 4 courses of R-CHOP-14 with etoposide (R-CHOEP) and 1 course
of high-dose cytarabine with R. In addition, liposomal cytarabine was administered
intrathecally at courses 1, 3, and 5. Coprimary endpoints were failure-free survival and CNS
progression rates. Thirty-six (26%) patients experienced treatment failure. Progression
occurred in 23 (16%) patients, including three (2.2%) CNS events. At 5 years of median
follow-up, failure-free survival, overall survival, and CNS progression rates were 74%,
83%, and 2.3%, respectively. Treatment reduced the risk of progression compared with our
previous trial, in which systemic CNS prophylaxis was given after 6 courses of biweekly
R-CHOEP (hazard ratio, 0.49; 95% CI, 0.31-0.77; P5 .002) and overcame the adverse impact of
an aaIPI score of 3 on survival. In addition, outcome of the patients with BCL2/MYC double-
hit lymphomas was comparable to the patients without the rearrangements. The results are
encouraging, with a low toxic death rate, low number of CNS events, and favorable survival
rates. This trial was registered at www.clinicaltrials.gov as #NCT01325194.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is a curable disease with
combination chemotherapy. The outcome is variable but can to
some extent be predicted from clinical risk factors included in the
International Prognostic Index (IPI) score.1 Combination of a CD20
targeted monoclonal antibody, rituximab (R), to cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP-14) or CHOP-21
regimens has substantially improved progression-free survival (PFS)
and overall survival (OS) in all elderly and young low-risk DLBCL
patients.2 However, dose densification of R-CHOP cycles from
21 to 14 days, or infusional dose-adjusted etoposide, prednisone,
vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-
R) has not provided further survival benefit.3-5
For young, clinically high-risk DLBCL patients, the optimal therapy
has not been established. Studies comparing conventional doses of
chemotherapy with high-dose therapy followed by autologous stem
cell transplantation have not convincingly shown an advantage for
high-dose therapy,6,7 and there is no randomized comparison of
the efficacy of adding R to chemotherapy in young, high-risk
patients. According to Nordic population-based studies, the
addition of etoposide (E) to an R-CHOP-14 regimen improves
OS of young high-risk patients.8,9 R-MegaCHOEP, in turn, is
not superior to R-CHOEP-14 and is associated with signifi-
cantly more toxicity.10 Likewise, rituximab plus hyperfractionated
cyclophosphamide, vincristine, doxorubicin, and dexamethasone
(R‐HCVAD)/rituximab, high-dose methotrexate (HD-Mtx), and
cytarabine (R‐MA) did not differ from R-CHOP with respect to
survival due to high treatment-related mortality.11
In addition to a high risk of systemic relapse, patients with DLBCL
are at risk for progression of their lymphoma in the central nervous
system (CNS). In the rituximab era, the rate and patterns of CNS
involvement with DLBCL have evolved.12 The overall risk of CNS
progression has been reduced to 5%; for high-risk patients with
more than one extranodal site and elevated lactate dehydrogenase
(LDH) levels, this risk is 10% to 15%,13-15 and particularly those
with renal or adrenal involvement.16 In addition, localization of CNS
relapse has shifted to the brain parenchyma in the majority of
cases.12
To the best of our knowledge, no study has shown in a prospec-
tive randomized fashion that CNS prophylaxis with intrathecal
or systemic Mtx prevents progression of lymphoma in the CNS.
German studies of non-Hodgkin lymphoma have shown that the
risk of CNS failure is reduced after addition of E or R to the CHOP
regimen.13,17 Furthermore, some retrospective analyses have shown
that HD-Mtx–based systemic CNS prophylaxis may reduce the
risk of CNS progression.18-20
The toxicity and efficacy of the R-CHOEP-14 regimen consolidated
with late systemic CNS prophylaxis in young high-risk patients
was investigated in a Nordic NLG-LBC-04 (CRY-04) study.21
Three-year OS and failure-free survival (FFS) rates were 81%
and 65%, respectively. Seven patients experienced CNS pro-
gression, all within 6 months of diagnosis, suggesting that the
patients had a subclinical disease at diagnosis. We hypothesized
that shifting of CNS prophylaxis to the beginning of the therapy
could overcome the subclinical disease, and thus reduce the risk
of early clinical CNS progression. To address the efficacy and
toxicity of early CNS prophylaxis, we initiated the NLG-LBC-05
(CHIC) study, in which systemic CNS prophylaxis with HD-Mtx was
given in the beginning of therapy, and CNS-targeted therapy further
intensified by adding intrathecally administered liposomal cytarabine.
Methods
Patients
Eligible patients were 18 to 64 years old with previously untreated,
histologically confirmed CD201 DLBCL or follicular lymphoma
grade 3B based on the World Health Organization 2008 Lymphoma
Classification.22 The following subgroups and variants were allowed:
ALK-positive largeB-cell lymphoma, mediastinal largeB-cell lymphoma,
intravascular large B-cell lymphoma, T-cell/histiocyte-rich large B-cell
lymphoma, and follicular lymphomas grade 3B. Patients with
posttransplantation lymphoma, discordant or transformed lym-
phoma, lymphomas intermediate between DLBCL and Burkitt’s
lymphoma, and primary CNS lymphoma were ineligible.
Patients had to present World Health Organization performance
status ,4, without clinical, radiologic, or cytologic signs of CNS
involvement with occult cerebrospinal fluid (CSF) involvement (flow
cytometry [FCM]-positive/cytology-negative) allowed, age-adjusted
IPI (aaIPI) score of 2 to 3,1 or specific risk factors for CNS recurrence
defined by more than one extranodal site, testicular lymphoma, stage
IIE and higher, paranasal sinus and orbital lymphoma with destruction
of bone, or large cell infiltration of the bone marrow, and adequate
organ function, allowing the planned treatment schedule. Additional
details on inclusion and exclusion criteria, and study procedures are
provided in the supplemental Methods.
The protocol was approved by the medical agencies and ethics
committees in Finland, Denmark, Norway, and Sweden, and the trial
was registered at ClinicalTrials.gov as #NCT01325194. All patients
signed informed consent before study participation.
Molecular pathology
Patients were included in the study based on a histological
diagnosis from the local pathologists. After inclusion, samples were
forwarded to the National Pathology Review representatives (E.R.,
S.S., K.B., and M.-L.K.-L.) for the confirmation of the diagnosis and
further subclassification into the 2 immunohistochemically defined
subgroups of germinal center B-cell type (GCB) and non-GCB
according to the Hans algorithm.23 Fluorescent in situ hybridization
analysis was performed retrospectively on available tissue microarray
or full paraffin-embedded 2- to 3-mm tissue sections by using the
break-apart probes for c-MYC/8q24,BCL2/18q21, andBCL6/3q27
(Vysis, Abbott Molecular). The assessment of Ki67-positivity was
conducted semi-quantitatively by the central pathology reviewer.
FCM immunophenotyping
CSF samples were directly collected into TransFix tubes (Immuno-
step SL) and shipped overnight to the central FCM laboratory in Oslo,
Norway. Samples were centrifuged, supernatant discarded, and the
cell pellet resuspended in phosphate-buffered saline. Immunophe-
notyping was performed by using multiparameter FCM as previously
described.24
Treatment
The study design is shown in Figure 1A and additional details on
treatment are described in the supplemental Methods.
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Statistical analyses
Coprimary end points were to estimate the proportion of
patients who were failure- and CNS progression-free at 3 and
1.5 years, respectively. FFS was defined as the interval between
the registration date and the date of documented progression
or lack of response, first relapse, death for any reason, or
discontinuation/change of therapy because of toxicity, which-
ever occurred first. Otherwise, patients were censored at the last
date they were known to be alive. For patients not responding at
any time point on study treatment, FFS is defined as day 1. CNS
recurrence was defined as the interval between registration date
and the date of documented CNS progression. Of the secondary
end points, OS was defined as the interval between the registration
date and death from any cause, and PFS as the period between the
registration date and lymphoma progression or death from any cause.
Other secondary end points were response rate, toxicity, biological risk
factors, and prognostic role of CSF (cytology-negative/FCM-positive)
for CNS recurrence.
Survival rates were estimated by using the Kaplan-Meier method.
Clinical and tumor-related factors were analyzed by using x2 tests
or nonparametric trend tests for response rates, and log-rank tests
and the Cox proportional hazards multivariate analysis for survival.
Statistical analyses were performed with SPSS version 25.0
(IBM SPSS Statistics, IBM Corporation). Probability values ,0.05
were considered statistically significant. All comparisons and all
comparative tests were 2-tailed.




Between March 2011 and December 2014, a total of 143
previously untreated patients, 18 to 64 years of age, were
recruited. At central pathology review, 2 cases were excluded as
non-DLBCL/non-grade 3B follicular lymphoma. One patient was
excluded due to a concomitant CNS lymphoma and one due to
concomitant cutaneous follicular lymphoma, leaving 139 evalu-
able patients (intention-to-treat population) (Figure 1B). The
majority of the patients had DLBCL (96%); the other subtypes are
specified in Table 1. The patient characteristics were typical for high-
risk DLBCL with a median age of 56 years (range, 20-64 years),
advanced clinical stage, elevated LDH level, more than one
extranodal site, and B symptoms. A bulky lesion (.10 cm) was
present in 37% of the patients, 45% had a high CNS-IPI score,
and 11 CSF samples (8%) were FCM-positive.
Most patients (n5 127; 96%) received the full treatment schedule.
The second cycle was given 19 days (median) after the first cycle,
which means a median delay of 2 days, while the third cycle was
given after 16 days (median) from the second cycle. The second
HD-Mtx dose was reduced or not given in 34% of the patients
mostly due to renal toxicity; reductions for the second doxorubicin
Dxm + vincristine + R prephase
HD-MTX+R-CHOP(D)14x2 and R-CHOED-14 with IT





 SD, PD  2nd-line, f-up for OS
 PR  viable tumour tissue 2nd-
line, f-up for OS
R-CHOEP(D)14x3 + IT liposomal
cytarabine cycle 5 R-cytarabine 12 g/m2
RT for bulky, EN or localized PET+ disease
Regular follow-up
 SD, PD  2nd-
line, f-up for OS
A
143 patients were included
4 were not eligible
• 2 changes of diagnosis
• 1 concomitant indolent
   lymphoma
• 1 CSF cytology+ at diagnosis
126 completed
chemoimmunotherapy
13 did not complete therapy
• 4 refractory
• 9 acute treatment related
  toxicities
36 received radiotherapy
• 21 bulky disease
• 26 residual disease




Figure 1. Study schema. (A) Trial profile. (B) Patient disposition. CR, complete response; CRu,complete response, unconfirmed; CSF, cerebrospinal fluid; EN, extranodal;
f-up, follow-up; IT, intrathecal; OS, overall survival; PD, progressive disease; PET, positron emission tomography; PR, partial response; RT, radiotherapy; SD, stable disease.
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and cyclophosphamide doses were performed in 6% and 6.5% of
patients, respectively. The second and the third cycles were
delayed by .1 week in 8.3% and 5.3% of the patients.
Intrathecal liposomal cytarabine was given to 81 (61%) patients and
omitted from the rest of the patients due to a transient production
halt. Local radiotherapy was administered to 39 (30%) patients;
25 patients received it due to a bulky lesion at diagnosis, and
17 patients due to lesions positive according to positron emission
tomography (PET) at the end of immunochemotherapy.
Biomarker analysis
CD10, BCL6, MUM/IRF4, BCL2, and CD5 positivity was observed
in 38 (30%), 104 (83%), 45 (38%), 96 (82%), and 10 (9%)
samples, respectively. On the basis of the Hans algorithm, 56 (54%)
of the patients were classified as GCB DLBCLs, and 47 (46%)
were classified as non-GCB DLBCLs. Double positivity for BCL2
and MYC (double protein expressor) was found in 15 (40%) of the
examined 38 samples. Among the samples displaying interpretable
fluorescent in situ hybridization signals, BCL2/18q21, BCL6/3q27,
and c-MYC/8q24 gene rearrangements were found in 23 (27%),
16 (19%), and 11 (14%) of the cases.BCL2/18q21 and c-MYC/8q24
rearrangements were strongly associated with the GCB subgroup
according to the Hans classifier (P5 .001 andP5 .007).BCL6/3q27
rearrangement was not correlated to either category. Double-hit
lymphomas (DHLs) were found in 9 (12%) of the examined 77
samples, all within the GCB subgroup. All DHL cases had advanced
stage, eight (85%) had elevated LDH levels, and three (33%) had
high CNS-IPI scores.
Toxicity and treatment failures
The fraction of patients with reported grade 3 to 4 toxic effects,
treatment failures due to acute and late toxicities, and toxic deaths
is shown in Table 2 and supplemental Table 1. Thirty-six patients
(26%) experienced treatment failure. Of these, 9 were due to
acute treatment-related toxicity and 20 due to primary refractory or
progressive lymphoma. Four patients developed acute myeloid
leukemia/myelodysplastic syndrome, one died of lung cancer, and
one from unknown reasons. Five patients died of treatment-related
toxicity.
Responses and survival
Response to therapy is summarized in supplemental Tables 2 and 3.
Eight patients were not evaluable for response due to toxicity. Of
the 119 patients who underwent PET/computed tomography (CT)
imaging at the end of immunochemotherapy, 91 (77%) achieved
a metabolic complete remission (CR), and 19 of 35 patients
(21%) with CT scan–based complete response unconfirmed/partial
remission were in metabolic CR according to PET/CT imaging. Of
note, only 1 (9%) of 11 biopsy samples from the PET-positive lesions
contained viable lymphoma.
After a median follow-up of 60 months, 23 patients had relapsed,
three in the CNS (1 with intermediate and 2 with high CNS-IPI
scores), of whom only 1 had pretherapeutic FCM-positive CSF.
Twenty-three had died, 16 due to lymphoma (supplemental Table 2).
Three-year FFS, CNS progression, PFS, and OS rates were 77%,
2.3%, 81%, and 86%, and corresponding 5-year rates were 74%,
2.3%, 81%, and 83%, respectively (Figure 2). Deauville score 5
at the end of treatment was associated with increased risk of
progression and death (Figure 3; supplemental Figure 1), whereas
other risk factors, such as aaIPI group (0-2 vs 3), number of
extranodal sites, and pretherapeutic FCM-positive CSF were
not associated with outcome.When the impact of chemotherapy on
survival was tested, there was a better PFS and OS rate in patients
who were treated with higher total Mtx doses ($3 g/m2). The
patients receiving lower total doses of Mtx had worse performance
Table 1. Patient characteristics (N 5 139)
Characteristic Value, n %




DLBCL NOS 113 81
GCB 56 49
Non-GCB 47 42
Not determined 10 9




Follicular lymphoma grade 3B 5 4.3
Not reviewed 7 5.0





B symptoms 88 63





Site-specific risk factor for CNS recurrence among aaIPI
score of 0-1
.1 extranodal site 5 3.6
Testicular lymphoma stage IIE or higher 2 1.4
Paranasal sinus and orbital lymphoma with destruction of bone 3 2.2
CNS IPI
Low (0-1 factor) 4 2.9
Intermediate (2-3 factors) 72 52
High ($4 factors) 63 45
Bulky disease 52 37
.1 extranodal sites 81 67
CSF FCM-positive 11 8
ECOG, Eastern Cooperative Oncology Group; NA, not applicable; NOS, not otherwise
specified; PMBCL, primary mediastinal B-cell lymphoma; PS, performance status; TCRB,
T-cell rich B-cell lymphoma.
*With site-specific risk factors for CNS recurrence defined by .1 EN site, testicular
lymphoma stage IIE and higher, paranasal sinus and orbital lymphoma with destruction of
bone, and large cell infiltration of the bone marrow.
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scores, higher aaIPI scores, and more treatment failures due to
toxicity. However, favorable prognostic impact of higher total Mtx
dose was sustained when adjusted by Eastern Cooperative
Oncology Group performance status (PFS hazard ratio [HR],
0.16; 95% confidence interval [CI], 0.05-0.49; P 5 .003), aaIPI
(PFS HR, 0.13; 95% CI, 0.04-0.37; P, .001), or toxicity (PFS HR,
0.17; 95% CI, 0.05-0.57; P 5 .004). Conversely, PFS and the
number of CNS events were not affected by intrathecal liposomal
cytarabine. When the association of biological markers with
outcome was examined, none of them correlated significantly with
survival.
Outcome for patients treated in the NLG-LBC-05 trial
compared with the previous NLG-LBC-04 trial
In the NLG-LBC-05 trial, patients more often had .1 extranodal
site than patients in the NLG-LBC-04 study,21 which served as
a preplanned historical control. Otherwise, patient demographic
characteristics and response rates were comparable between the 2
trial cohorts (supplemental Table 4). However, the LBC-05 regimen
improved outcome over LBC-04 in terms of better 5-year FFS and
PFS (Figure 4A,C). The differences in 5-year OS and cumulative
incidence rates of CNS recurrence did not reach statistical
significance (Figure 4B,D). A favorable impact of the LBC-05
regimen on PFS was particularly evident among the patients
aged,60 years or with an aaIPI score of 3 (Figure 4E; supplemental
Figure 2). In multivariate analysis, which included age, aaIPI
score, molecular subtype, and regimen, the aaIPI score and
regimen remained independent prognostic factors for progression
(supplemental Table 5).
To investigate the impact of early HD-Mtx on the outcome within the
biological subgroups, the patients were divided according to
their biological subgroup and study cohort. In the entire study
population, double-protein expressor of BCL2 and c-MYC was
the only marker to be significantly correlated with a worse
outcome (5-year PFS 77% vs 50%; HR, 2.30; 95% CI, 1.087-
4.851; P 5 .029). No single immunohistochemical marker or the
GCB/non-GCB subtype or DHL status significantly affected
outcome. However, when treatment interaction in the 2 Nordic
studies was tested, DHL status was associated with a worse
PFS and OS after the LBC-04 regimen (P5 .011 and P5 .001), as
previously reported25 and now updated at the 75-month median
follow-up. DHL had no adverse prognostic impact among the
patients who received the LBC-05 regimen (P 5 .99) (supplemen-
tal Figure 2).
Discussion
To our knowledge, the current study is the largest prospective study
to date addressing efficacy and toxicity of early systemic CNS
prophylaxis and dose-dense immunochemotherapy in patients aged
,65 years with high-risk aggressive B-cell lymphoma. The study
had two coprimary end points: to determine if early administration of
HD-Mtx–based CNS prophylaxis followed by dose-dense immuno-
chemotherapy could reduce the incidence of early CNS progres-
sions and improve FFS. Even if our study was not powered to show
a significant reduction in the CNS recurrence rate, we observed
fewer CNS events than in our previous LBC-04 study21 and could
report a better systemic control of the disease and superior 3-year
FFS (77% vs 63%) and PFS (81% vs 66%) rates. A relatively
low toxic death rate of 3.6% showed that the intensive regimen
is feasible for most of the patients. Overall, the LBC-05 regimen
seemed to be better tolerated than other intensive treatment
approaches.5,10,11 It is thus possible that the favorable outcome is
partially related to lower toxicity, which does not interfere with the
therapeutic efficacy.
Since the design and initiation of our trial, a specific model to estimate
the risk of CNS recurrence, the CNS-IPI, has been established and
validated.16 Some biological risk factors have also been described. In
particular, DHL and double-protein expressor lymphomas, and occult
CSF involvement (FCM-positive/cytology-negative) have been asso-
ciated with increased risk of CNS relapse in retrospective series.26-28
Molecular CNS-IPI was also recently presented.29 In our study,
53% of the patients were categorized to the high-risk group
according to CNS-IPI score, or biological risk factors such as
DHL despite low or intermediate CNS-IPI scores (8%) with the
expected CNS recurrence rate of 10% to 12%.16 However, we
observed only 3 CNS events, translating to a 2.3% CNS
recurrence rate in 5 years. Because neither the occult CSF
involvement nor the DHL entity was associated with the risk of
CNS recurrence, it is plausible to suggest that the LBC-05
regimen may overcome the adverse prognostic impact of both
clinical and biological risk factors. Conversely, 47% of the
patients had low or intermediate risk of CNS recurrence with
the expected CNS recurrence rate ,5%, and CNS prophylaxis
may not be justified for this group. However, as HD-Mtx could
also improve systemic control of the disease, it remains to be
confirmed whether or to what extent the low number of CNS relapses
observed in our study is a consequence of a better systemic efficacy
of early administration of HD-Mtx.
Table 2. Feasibility and toxicity
Variable n %
Adverse event (grades >2)
Grade 4 infection 16 12
Grade 3-4 mucositis 28 20
Grade 3 arachnoiditis 2 1.4
Grade 3-4 gastrointestinal toxicity 28 20
AML/MDS 4 3.1
PML 1 0.7




















 https://ashpublications.org/bloodadvances/article-pdf/4/9/1906/1727855/advancesadv2020001518.pdf by guest on 11 June 2020
Given the conflicting evidence base, lack of prospective random-
ized studies, and potential toxicity, there is no consensus whether,
how, when, and to which patient groups CNS prophylaxis should
be given. Retrospective analyses have shown that systemic CNS
prophylaxis may reduce the risk of CNS relapses.18-20 In our
previous trial,21 a CNS relapse rate of 4.5% was observed. In the
current study, we aimed to reduce CNS relapse rate further without
compromising systemic efficacy by combining sensitive FCM-based
CSF detection analysis with earlier and more intensive systemic and
intrathecally targeted CNS prophylaxis. Although shifting of HD-Mtx
to the beginning of the therapy translated to significantly improved
FFS, PFS, and low number of CNS events, intrathecally adminis-
tered liposomal cytarabine failed to show any additional benefit.
This scenario may be related to restricted penetration of intrathecal
therapy to the brain parenchyma, which is the predominant
location of CNS recurrence in DLBCL.12,30 We also analyzed the
impact of Mtx dose and, irrespective of the impact on CNS events,
found a significant quantitative association between the dose
and survival. Overall, our results are promising and emphasize the
importance of timing and dose of systemic HD-Mtx administration
for optimal systemic control of lymphoma. Consistent with our
findings, recent retrospective studies have shown that addition of
HD-Mtx to a CHOP/R-CHOP regimen improves the prognosis
of patients with high-risk DLBCL, irrespective of their risk for CNS
relapse.31-33 Whether or to what extent the low number of CNS
relapses observed in our study is a consequence of a systemic
efficacy of early administration of HD-Mtx needs to be confirmed
in a randomized study.
We also assessed whether PET positivity (Deauville score 4-5)
at the end of immunochemotherapy could identify patients,
who are unlikely to be cured with the NLG-LBC-05 regimen. As
expected, we found that majority of the patients (80%) with
negative fluorodeoxyglucose PET scans (Deauville score 1-3)
achieved long-term metabolic remission, and 42% of the patients
with Deauville score 5 relapsed. In contrast, the outcome of those
with Deauville score 4 was comparable to those of PET-negative
patients. Of note was also the finding that only 9% from the
PET-positive lesions contained viable lymphoma. The observa-
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Figure 2. Survival analyses. Kaplan-Meier survival estimates for FFS (A), risk of CNS relapse (B), PFS (C), and OS (D).
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relapse from PET- positive lesions and a possible favorable
impact of consolidating radiotherapy.
Our exploratory analyses on clinical variables uncovered the
influence of age on treatment tolerability and outcomes. Although
in patients aged,60 years, the LBC-05 regimen showed clinically
meaningful survival benefit over the LBC-04 regimen with manage-
able safety, in patients aged $60 years, toxicity was possibly
confounding the therapeutic benefit. In addition, the benefit of
the LBC-05 regimen was particularly noted in patients with an
aaIPI score of 3. Based on the findings, we propose intensified
therapy with early CNS prophylaxis for high-risk patients,60 years,
whereas in this setting the regimen should be cautiously considered
for patients aged $60 years.
We were also interested in the impact of the LBC-05 regimen on
the outcome of patients with DHL. Several retrospective studies have
shown that R-CHOP is not a sufficient therapy for patients with DHL
and have proposed that more intensive Burkitt-like regimens, such as
dose-adjusted EPOCH-R, R-HyperCVAD/MA, or R-CODOX-M/IVAC,
should be used.26,34 Of these, the R-CODOX-M/IVAC regimen has
recently been tested for the patients with high-risk DLBCL/high-grade
B-cell lymphoma also in a phase 2 trial, and reported to have efficacy
similar to high-risk Burkitt lymphoma.35 We found that the
outcome of the patients with DHL was comparable to that of all
other patients, whereas no such impact could be seen in the
previous LBC-04 trial.25 It is thus plausible to suggest that early
administration and/or a higher Mtx dose may overcome the
adverse prognostic impact of DHL. The overall conclusion of this
and previous studies is that the patients with DHL may benefit
from more intensive treatment.
This study had several limitations. First, it was not powered to
detect a statistically significant reduction in CNS events. Overall,
the benefit of CNS prophylaxis should be ideally addressed in an
adequately sized, randomized phase 3 study. The encouraging
results on outcome of the few patients with DHL must also be
interpreted with caution. Second, because the conclusions based
on historical comparisons may be subject to differences in observed
and unobserved prognostic factors, we cannot exclude the possibility
that a better outcome in response to the LBC-05 regimen is related
to factors other than treatment. Finally, exploratory analyses of
prognostic variables were also limited by small numbers and
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Figure 3. Subgroup analyses. Forest plot showing subgroup analysis of PFS. Ara-C, cytarabine; DPE, double-protein expressor; EN, extranodal; PS, performance status.
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Figure 4. Comparison of survival rates between LBC-04 and LBC-05 trials. Kaplan-Meier survival estimates for FFS (A), PFS (B), OS (C), and risk of CNS relapse
(D) according to the LBC-04 and LBC-05 trials. (E) Forest plot showing subgroup analysis of PFS in the LBC-04 vs LBC-05 trials. In panel E, PFS in case of all patients is
adjusted for aaIPI score.




 https://ashpublications.org/bloodadvances/article-pdf/4/9/1906/1727855/advancesadv2020001518.pdf by guest on 11 June 2020
Taken together, we were able to show highly satisfactory PFS, OS,
and CNS progression rates for young patients with high risk B-cell
lymphoma in response to early HD-Mtx–based CNS prophylaxis
followed by dose-dense immunochemotherapy. The LBC-05 regimen
was also well tolerated, and it can be considered as an alternate
treatment option for young patients with high-risk aggressive B-cell
lymphomas. Identifying the biologically high-risk group and combining
the regimen with novel agents seem to be the most logical next steps
to further improve the outcome for this high-risk patient population.
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